Floatz logo

Bydureon

Left Ventricular Diastolic Dysfunction

Baylor Research InstitutePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Left Ventricular Diastolic Dysfunction cohort.

Asset / SponsorPhaseRating
Tirzepatide
Yunlong Wang
Phase 4BBB
Semaglutide
Mayo Clinic
Phase 4BBB
Metformin
Sara ElAdawy
Phase 4BBB
Liraglutide
Leiden University Medical Center
Phase 4BBB
Tadalafil
Kafrelsheikh University
Phase 4BB

View all 23 →

Same molecule, other indications

Bydureon is also rated in:

type 2 diabetes mellitusDormant
B
Indicative ·
62 / 100
View asset →
chronic kidney diseaseDormant
B
Indicative ·
60 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →